Gilead Sciences, Inc.

9 Active Projects

Title Investigator Start End
Grant to support UCSF Global Health Impact Fund Feachem
Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B Khalili
GS-US-382-3961: A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers Deeks
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching from Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects with Chronic Hepatitis B who are Virologically Suppressed Khalili
Sustainable East Africa Research in Community Health Havlir
A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients with Chronic Hepatitis B Infection Rosenthal
Phase 2, Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children with Genotype 2 or 3 Chronic HCV Infection Rosenthal
GS-US-380-4030: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Co Luetkemeyer
Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination in Adolescents and Children with Chronic HCV-Infection Rosenthal

19 Archived Projects

Title Investigator Start End
Gilead Drug Donation for Antiretroviral Therapy of AIDS-Related Kaposi's Sarcoma in Africa Martin
Atripla Adherence and Resistance Relationships [I] Deeks
Treating HIV-infected Elite Controllers as a Model of HIV Remission Deeks
Gilead GS-US-236-0102 Luetkemeyer
Protocol GS-US-334-0139 An Expanded Access Phase 2 Study of Sofosbuvir and Ribavarin with or without Pegylated Interferon for 24 Weeks in Subjects Who Have Undergone Liver Transplantation and Who Have Aggressive Recurrent Hepatitis C Infection
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of GS-7977 plus Ribavirin for 12 Weeks in Chronic Genotype 2 and 3 Hepatitis C Virus (HCV) Coinfected Subjects (GS-US-334-0123) Luetkemeyer
Gilead HCAT Support-SOMA Project Dilley
Tenofovir Kidney Toxicity Study
GS_US_342-1139: Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 12 Weeks in Subjects with Chronic Genotype 2 HCV Infecti Luetkemeyer
GS-US-183-0130: A Phase 3, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 (GS-9137/r) Administered in Combination with Other Antiretroviral Agents in the Treatment of HIV-1 Infected Subjects Luetkemeyer
A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 weeks in Subjects with Chronic HCV and HIV-1 Coinfection Luetkemeyer
Early Antiretroviral Therapy in Resource Limited Settings in Patients with High CD4+ Cell Counts Jain
Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Subjects with Chronic Hepatitis C Luetkemeyer
Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Subjects with Chronic Hepatitis C Luetkemeyer
GS-US-248-0122: A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection Khalili
Patients' HBV Knowledge, Attitudes, Barriers to HBV Care and HBV Treatment Khalili
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Ledipasvir/Sofosbuvir in Subjects with Genotype 1, 4, 5 and 6 Chronic HCV Infection Who are on Dialysis for End Stage Renal Disease Khalili
Early Antiretroviral Therapy in Resource Limited Settings in Patients with High CD4+ Cell Counts Jain
GS-US-367-1172: A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Khalili